NASDAQ:DWTX Dogwood Therapeutics (DWTX) Stock Price, News & Analysis $1.26 -0.04 (-3.08%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Dogwood Therapeutics Stock (NASDAQ:DWTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dogwood Therapeutics alerts:Sign Up Key Stats Today's Range$1.27▼$1.3450-Day Range$1.30▼$2.6852-Week Range$1.27▼$7.04Volume57,543 shsAverage Volume76,219 shsMarket Capitalization$42.83 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Dogwood Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression. Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID. The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development. Its programs remain investigational and are subject to clinical testing and regulatory review. Publicly available information about its geographic operations and leadership is limited.AI Generated. May Contain Errors. Read More Dogwood Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreDWTX MarketRank™: 3.10915539209 of 5 starsDogwood Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 345th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDogwood Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialDogwood Therapeutics has a consensus price target of $12.00, representing about 826.6% upside from its current price of $1.30.Amount of Analyst CoverageDogwood Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Dogwood Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dogwood Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dogwood Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dogwood Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDogwood Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Dogwood Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.11% of the float of Dogwood Therapeutics has been sold short.Short Interest Ratio / Days to CoverDogwood Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dogwood Therapeutics has recently decreased by 47.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDogwood Therapeutics does not currently pay a dividend.Dividend GrowthDogwood Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.71 News SentimentDogwood Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Dogwood Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Dogwood Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.30% of the stock of Dogwood Therapeutics is held by insiders.Percentage Held by Institutions9.05% of the stock of Dogwood Therapeutics is held by institutions.Read more about Dogwood Therapeutics' insider trading history. Receive DWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DWTX Stock News HeadlinesDogwood Therapeutics (NASDAQ:DWTX) Stock Price Down 5.9% - Time to Sell?October 8, 2026 | americanbankingnews.comDogwood to Participate in the 2026 Maxim Growth SummitOctober 6, 2026 | globenewswire.comTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.October 14 at 1:00 AM | Monument Traders Alliance (Ad)Dogwood Therapeutics Stock Price HistorySeptember 15, 2026 | investing.comDogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due NovemberSeptember 14, 2026 | rttnews.comDogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b TrialSeptember 14, 2026 | globenewswire.comBiotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In FocusSeptember 8, 2026 | rttnews.comDogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain TranscriptSeptember 2, 2026 | seekingalpha.comSee More Headlines DWTX Stock Analysis - Frequently Asked Questions How have DWTX shares performed this year? Dogwood Therapeutics' stock was trading at $4.16 at the start of the year. Since then, DWTX stock has decreased by 68.9% and is now trading at $1.2950. How were Dogwood Therapeutics' earnings last quarter? Dogwood Therapeutics, Inc (NASDAQ:DWTX) released its earnings results on Thursday, August, 13th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.20. When did Dogwood Therapeutics' stock split? Dogwood Therapeutics shares reverse split on the morning of Wednesday, October 9th 2024.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Dogwood Therapeutics IPO? Dogwood Therapeutics (DWTX) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. How do I buy shares of Dogwood Therapeutics? Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/14/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DWTX's financial health is in the Yellow zone, according to TradeSmith. DWTX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DWTX CIK1818844 Webwww.virios.com Phone(866) 620-8655FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for Dogwood Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+826.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.55% Return on Assets-40.28% Debt Debt-to-Equity RatioN/A Current Ratio3.89 Quick Ratio3.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book0.56Miscellaneous Outstanding Shares33,990,000Free Float33,891,000Market Cap$44.02 million OptionableN/A Beta1.92 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:DWTX) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
